Goldman Sachs’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $118M | Buy |
541,500
+306,900
| +131% | +$68.1M | 0.01% | 934 |
|
|
2025
Q4 | $53.6M | Buy |
234,600
+58,500
| +33% | +$13.3M | 0.01% | 1457 |
|
|
2025
Q3 | $40.8M | Sell |
176,100
-1,900
| -1% | -$387K | 0.01% | 1595 |
|
|
2025
Q2 | $33M | Sell |
178,000
-33,800
| -16% | -$6.28M | ﹤0.01% | 1673 |
|
|
2025
Q1 | $44.4M | Buy |
211,800
+97,600
| +85% | +$19M | 0.01% | 1313 |
|
|
2024
Q4 | $20.3M | Sell |
114,200
-465,300
| -80% | -$85.5M | ﹤0.01% | 2121 |
|
|
2024
Q3 | $114M | Buy |
579,500
+211,000
| +57% | +$39.4M | 0.02% | 733 |
|
|
2024
Q2 | $63.2M | Sell |
368,500
-386,500
| -51% | -$64M | 0.01% | 1007 |
|
|
2024
Q1 | $137M | Buy |
755,000
+315,600
| +72% | +$54.4M | 0.02% | 625 |
|
|
2023
Q4 | $68.1M | Sell |
439,400
-144,800
| -25% | -$21.1M | 0.01% | 977 |
|
|
2023
Q3 | $87.1M | Buy |
584,200
+291,700
| +100% | +$42.8M | 0.02% | 790 |
|
|
2023
Q2 | $39.4M | Sell |
292,500
-138,100
| -32% | -$20.3M | 0.01% | 1277 |
|
|
2023
Q1 | $68.6M | Sell |
430,600
-771,900
| -64% | -$118M | 0.02% | 869 |
|
|
2022
Q4 | $194M | Buy |
1,202,500
+1,040,200
| +641% | +$159M | 0.05% | 423 |
|
|
2022
Q3 | $21.8M | Sell |
162,300
-61,800
| -28% | -$8.87M | 0.01% | 1789 |
|
|
2022
Q2 | $34.3M | Sell |
224,100
-182,000
| -45% | -$27.8M | 0.01% | 1425 |
|
|
2022
Q1 | $65.8M | Sell |
406,100
-209,900
| -34% | -$30.5M | 0.01% | 1057 |
|
|
2021
Q4 | $83.4M | Buy |
616,000
+74,600
| +14% | +$8.81M | 0.02% | 925 |
|
|
2021
Q3 | $58.4M | Sell |
541,400
-334,400
| -38% | -$38.2M | 0.01% | 1171 |
|
|
2021
Q2 | $98.7M | Buy |
875,800
+490,800
| +127% | +$55.3M | 0.02% | 743 |
|
|
2021
Q1 | $41.7M | Sell |
385,000
-294,400
| -43% | -$31.5M | 0.01% | 1312 |
|
|
2020
Q4 | $72.8M | Buy |
679,400
+483,700
| +247% | +$46.5M | 0.02% | 823 |
|
|
2020
Q3 | $17.1M | Sell |
195,700
-72,200
| -27% | -$6.8M | ﹤0.01% | 1853 |
|
|
2020
Q2 | $26.3M | Sell |
267,900
-88,200
| -25% | -$7.77M | 0.01% | 1456 |
|
|
2020
Q1 | $27.1M | Sell |
356,100
-183,500
| -34% | -$15.6M | 0.01% | 1291 |
|
|
2019
Q4 | $47.8M | Buy |
539,600
+70,300
| +15% | +$5.84M | 0.01% | 1173 |
|
|
2019
Q3 | $35.5M | Sell |
469,300
-132,200
| -22% | -$9.06M | 0.01% | 1344 |
|
|
2019
Q2 | $43.7M | Buy |
601,500
+449,600
| +296% | +$35.3M | 0.01% | 1229 |
|
|
2019
Q1 | $12.2M | Sell |
151,900
-107,100
| -41% | -$8.76M | ﹤0.01% | 2257 |
|
|
2018
Q4 | $23.9M | Buy |
259,000
+200,300
| +341% | +$17.6M | 0.01% | 1661 |
|
|
2018
Q3 | $5.55M | Buy |
58,700
+400
| +0.7% | +$37.9K | ﹤0.01% | 2906 |
|
|
2018
Q2 | $5.4M | Buy |
58,300
+17,000
| +41% | +$1.66M | ﹤0.01% | 2909 |
|
|
2018
Q1 | $3.91M | Sell |
41,300
-135,400
| -77% | -$14.9M | ﹤0.01% | 3091 |
|
|
2017
Q4 | $17.1M | Sell |
176,700
-1,544,300
| -90% | -$146M | ﹤0.01% | 2054 |
|
|
2017
Q3 | $153M | Buy |
1,721,000
+1,232,100
| +252% | +$93.8M | 0.04% | 559 |
|
|
2017
Q2 | $35.5M | Sell |
488,900
-196,000
| -29% | -$13.2M | 0.01% | 1498 |
|
|
2017
Q1 | $44.6M | Buy |
684,900
+255,900
| +60% | +$16.1M | 0.01% | 1298 |
|
|
2016
Q4 | $26.9M | Sell |
429,000
-191,000
| -31% | -$11.7M | 0.01% | 1745 |
|
|
2016
Q3 | $39.1M | Buy |
620,000
+175,800
| +40% | +$11.4M | 0.01% | 1390 |
|
|
2016
Q2 | $27.5M | Sell |
444,200
-351,800
| -44% | -$21.4M | 0.01% | 1560 |
|
|
2016
Q1 | $45.5M | Buy |
796,000
+432,100
| +119% | +$24.1M | 0.01% | 1145 |
|
|
2015
Q4 | $21.6M | Sell |
363,900
-157,200
| -30% | -$9.05M | 0.01% | 1700 |
|
|
2015
Q3 | $28.4M | Sell |
521,100
-379,100
| -42% | -$24.7M | 0.01% | 1465 |
|
|
2015
Q2 | $60.5M | Buy |
900,200
+242,900
| +37% | +$15.9M | 0.02% | 984 |
|
|
2015
Q1 | $38.5M | Sell |
657,300
-909,800
| -58% | -$55M | 0.01% | 1291 |
|
|
2014
Q4 | $103M | Buy |
1,567,100
+563,400
| +56% | +$35.5M | 0.03% | 667 |
|
|
2014
Q3 | $58M | Buy |
1,003,700
+738,800
| +279% | +$41M | 0.02% | 967 |
|
|
2014
Q2 | $15M | Sell |
264,900
-153,100
| -37% | -$8.03M | ﹤0.01% | 2035 |
|
|
2014
Q1 | $21.5M | Sell |
418,000
-331,600
| -44% | -$16.8M | 0.01% | 1708 |
|
|
2013
Q4 | $39.6M | Buy |
749,600
+495,900
| +195% | +$24.4M | 0.01% | 1220 |
|
|
2013
Q3 | $11.3M | Buy |
253,700
+100,800
| +66% | +$4.47M | ﹤0.01% | 2126 |
|
|
2013
Q2 | $6.32M | Buy |
+152,900
| New | +$6.69M | ﹤0.01% | 2506 |
|
Other funds holding ABBV
VCM
VPM
Goldman Sachs's ABBV Position: Q1 2026 in Review
Goldman Sachs increased its AbbVie (ABBV) stake by 17% in Q1 2026, buying an estimated $477M and bringing the position to 15,145,279 shares worth $3.29B. The position accounts for 0.38% of the portfolio, ranked #28.
Goldman Sachs first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Goldman Sachs held 15,145,279 shares of AbbVie worth $3.29B as of Q1 2026.
- Goldman Sachs bought 2,149,654 AbbVie shares in Q1 2026, an estimated $477M.
- AbbVie made up 0.38% of Goldman Sachs's portfolio in Q1 2026, its #28 holding.
- Goldman Sachs first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
- 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.